Among a United States military unit of 170 personnel deployed to Utapao, Thailand for a three-week training exercise, 40% experienced diarrheal disease, and 12% sought medical treatment for diarrhea. Most illness clustered within the first two weeks of arrival and individuals were ill an average of 3.6 days. Fifty-five percent of cases lost two days of work and 15% required treatment with intravenous fluids. Bacterial pathogens were recovered from 38% of 16 stools submitted, with Campylobacter jejuni the most common. Four (12.5%) of 32 persons who voluntarily submitted paired sera exhibited a four-fold increase in IgG antibody titer to C. jejuni. Traveler's diarrhea continues to be an important problem with a serious potential to impact the mission readiness of even small military units deployed overseas.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4269/ajtmh.1997.57.699 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON.
Lung
January 2025
National Reference Center for Rare Pulmonary Diseases, Louis Pradel Hospital, Hospices Civils de Lyon, Claude Bernard University Lyon 1, UMR 754, ERN-LUNG, Lyon, France.
Purpose: In the INBUILD trial in patients with progressive pulmonary fibrosis (PPF), nintedanib slowed the decline in forced vital capacity (FVC) versus placebo, with a safety profile characterised mainly by gastrointestinal events. INBUILD-ON, the open-label extension of INBUILD, assessed the safety of nintedanib during longer-term treatment. Data on FVC were collected.
View Article and Find Full Text PDFDevelopment and Evaluation of a Remote Monitoring Regional Adjuvant Abemaciclib Service for Patients With High-Risk Early Breast Cancer.
Clin Breast Cancer
December 2024
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK; Division of Cancer Sciences, The University of Manchester, Manchester, UK. Electronic address:
Introduction: Adjuvant abemaciclib was recently approved in high-risk early breast cancer, leading to an increase in oncology resource utilisation. We thus developed a regional, remote monitoring clinical service. The set-up, delivery processes and outcomes from the first 6 months' consecutive patients are presented.
View Article and Find Full Text PDFA phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.
Gynecol Oncol
January 2025
Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Introduction: Molecular alterations in the PI3K/AKT and Ras/Raf/MEK/ERK pathways are frequently observed in patients with endometrial cancers. However, mTOR inhibitors, such as temsirolimus, have modest clinical benefits. In addition to inducing metabolic changes in cells, metformin activates AMPK, which in turn inhibits the mTOR pathway.
View Article and Find Full Text PDFDescribing quality of life trajectories in young Hispanic women with breast cancer: 5-year results from a large prospective cohort.
Breast
December 2024
Breast Cancer Center, Hospital Zambrano Hellion TecSalud, Tecnologico de Monterrey, San Pedro Garza García, Mexico; MILC, Médicos e Investigadores en la Lucha contra el Cáncer de Mama, Ciudad De México, Mexico. Electronic address:
Introduction: Cancer treatments have a detrimental impact on the quality of life (QoL) of young women with breast cancer (YWBC). Research exploring QoL trajectories has been mostly centered on postmenopausal women. Here we report longitudinal changes across all QoL domains and associated factors in YWBC.
View Article and Find Full Text PDFValidation and evaluation of the performance of QIAstat-Dx gastrointestinal panel in pooled stool samples.
Acta Trop
December 2024
Key Laboratory of Diarrhea Disease Detection, Zhuhai International Travel Healthcare Center, Zhuhai 519020, Guangdong, PR China. Electronic address:
In the current study, the analytical sensitivity, analytical specificity, reproducibility, anti-interferences ability, and clinical performance of the QIAstat-Dx Gastrointestinal Panel (GIP) system were evaluated using pooled stool samples. Results showed that the pooled sample test detected the selected ten targets exclusively, with no cross reaction with any other targets of common enteropathogens. The analytical sensitivity of the pooled sample test on QIAstat-Dx GIP system was 10 CFU/ml for Shigella spp.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!